Noopept (also known by its development code GVS-111; chemically N-phenylacetyl-L-prolylglycine ethyl ester) sits in a peculiar niche. In some countries it is used clinically as a nootropic for cognitive symptoms after brain injury or vascular disease; elsewhere it is sold online as a supplement-like cognitive enhancer.

That split identity matters, because the public conversation around noopept often implies a depth of human evidence that—judging from the peer-reviewed clinical literature—is still fairly thin. A recurring theme across modern reviews is that noopept’s clinical evidence base is small compared with its popularity.

A report from the Alzheimer’s Drug Discovery Foundation notes that, despite widespread interest, published human data are limited and dominated by a single short clinical study, with no ongoing trials found in their search.

Evidence for cognitive enhancement

The most frequently cited clinical dataset comes from an open-label comparative study in patients with mild cognitive disorders linked to cerebrovascular disease or post-traumatic CNS conditions (G. G. Neznamov and E. S. Teleshova 2009).

In the noopept group, the Mini-Mental State Examination (MMSE) increased from 26 to 29 over 56 days on a regimen of 10 mg twice daily. Reported side effects in the noopept group included sleep disturbances in 5/31, irritability in 3/31, and increased blood pressure in 7/31.

A separate clinical report examined noopept in stroke patients (A. V. Amelin et al. 2011). The study describes 60 patients and reports that noopept (given at 20 mg daily) was associated with significant improvement after 2 months on the MMSE and certain neuropsychological association tests compared with controls; it also describes a “high level of safety.”

One unusual angle in the human literature is electrophysiology. An EEG-focused study (V. K. Bochkarev et al. 2008) reports that noopept shifted brain rhythms in directions considered typical for nootropics: increased alpha and beta power with reduced delta power.

Specifically, alpha changes mainly in 6.7–10.2 Hz sub-bands, and beta changes differed by region (augmented frontally and attenuated occipitally). The authors interpret the overall pattern as “nonspecific activation” plus an “anxiolytic effect,” with effects more obvious in vascular disease than post-traumatic cases.

EEG findings like these are suggestive—they show the brain is responding—but they don’t automatically translate into real-world improvements in learning, attention, or memory. They do, however, fit with the clinical framing of noopept as a neuropsychiatric “normalizer” rather than a pure stimulant.

Possible Mechanism of Action

In cultured human cortical neurons exposed to oxidative injury, A. Pelsman et al. (2003) reported that a 50 µM H₂O₂ exposure for 1 hour led to degeneration of more than 60% of neurons in culture, and that GVS-111 (noopept) increased neuronal survival across 10 nM to 100 µM, with an IC₅₀ of 1.21 ± 0.07 µM.

This kind of result supports a plausible “neuroprotection under stress” narrative—relevant to injury or neurodegenerative contexts—while being one step removed from cognitive enhancement in healthy brains.

A widely cited hypothesis is that noopept influences trophic signaling related to synaptic plasticity. In rats, R. U. Ostrovskaya et al. (2008) reported that noopept altered mRNA expression for NGF and BDNF, with effects depending on acute versus chronic administration (28 days).

In the hippocampus, expression of mRNA for both neurotrophins increased after acute administration, and chronic treatment did not show tolerance and “potentiated” the effect.

Notably, the abstract describes the direction of changes but not a clean set of percent changes or fold-differences, which limits how quantitatively we can interpret the magnitude from the abstract alone. Still, the hippocampus-focused directionality fits a memory-relevant mechanism.

A pharmacokinetic complication is that noopept itself appears short-lived (at least in rodents). The ADDF report summarizes that noopept has a ~5–10 minute half-life in rodents and is not present in the brain one hour after administration, while its metabolite cycloprolylglycine (cPG) is increased in the brain at about one hour and may mediate longer-term effects (citing older work).

That framing—“short parent compound, longer-acting metabolite”—is common in neuropharmacology, and it offers a coherent way to reconcile rapid clearance with behavioral effects observed hours later in animals.

Noopept as a nootropic

In clinical contexts, the best-supported claim is modest improvement in cognitive symptoms in certain patient groups—particularly mild cognitive disorders of vascular or post-injury origin—based on small, largely regionally published studies and limited reporting detail in widely accessible sources.

The most concrete numeric signal in humans is the MMSE change from 26 to 29 over 56 days in one study, alongside side effects that were not rare (e.g., 7/31 reporting increased blood pressure).

For healthy people seeking “upgrade” effects, the evidence is much weaker: the clinical literature is not built around randomized, placebo-controlled trials in healthy adults measuring attention, working memory, learning rate, or executive function.

The mechanistic data (oxidative stress protection, neurotrophin signaling, synaptic modulation) could be relevant, but they don’t substitute for human performance trials.

Noopept is best described, based on current clinical literature, as a candidate symptomatic cognitive aid studied mainly in post-vascular and post-traumatic cognitive impairment, with limited, modest, and incompletely replicated human evidence, and a larger body of mechanistic/preclinical work suggesting routes by which it might influence memory-relevant neurobiology. The gap between “plausible mechanism” and “reliable cognitive enhancement”—especially in healthy users—remains substantial.

References

Alzheimer’s Drug Discovery Foundation (ADDF). Cognitive Vitality Reports®: Noopept (n.d.). “https://www.alzdiscovery.org/uploads/cognitive_vitality_media/Noopept-Cognitive-Vitality-For-Researchers.pdf
“

G. G. Neznamov, E. S. Teleshova (2009). Comparative studies of Noopept and piracetam in the treatment of patients with mild cognitive disorders in organic brain diseases of vascular and traumatic origin. “https://pubmed.ncbi.nlm.nih.gov/19234797/
“

V. K. Bochkarev, S. A. Siuniakov, D. V. Davydova (2008). [Clinical and electroencephalographic characteristic of noopept in patients with mild cognitive impairment of posttraumatic and vascular origin]. “https://pubmed.ncbi.nlm.nih.gov/19008801/
“

A. V. Amelin, A. Iu. Iliukhina, A. A. Shmonin (2011). [Noopept in the treatment of mild cognitive impairment in patients with stroke]. “https://pubmed.ncbi.nlm.nih.gov/22500312/
“

Alejandra Pelsman, Carlos Hoyo-Vadillo, Tatiana A. Gudasheva, Sergei B. Seredenin, Rita U. Ostrovskaya, Jorge Busciglio (2003). GVS-111 prevents oxidative damage and apoptosis in normal and Down’s syndrome human cortical neurons. “https://pubmed.ncbi.nlm.nih.gov/12711349/
“

Ostrovskaya, Gudasheva, A. P. Zaplina, Ju. V. Vahitova, M. H. Salimgareeva, R. S. Jamidanov, S. B. Seredenin (2008). Noopept stimulates the expression of NGF and BDNF in rat hippocampus. “https://pubmed.ncbi.nlm.nih.gov/19240853/
“

Pieter A. Cohen, Bharathi Avula, Yan-Hong Wang, Igor Zakharevich, Ikhlas Khan (2021). Five Unapproved Drugs Found in Cognitive Enhancement Supplements. “https://pubmed.ncbi.nlm.nih.gov/34484905/
“